GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (HKSE:03320) » Definitions » Cash Flow from Investing

China Resources Pharmaceutical Group (HKSE:03320) Cash Flow from Investing : HK$-2,261 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the six months ended in Dec. 2023, China Resources Pharmaceutical Group spent HK$1,566 Mil on purchasing property, plant, equipment. It gained HK$167 Mil from selling property, plant, and equipment. It spent HK$76 Mil on purchasing business. It gained HK$-304 Mil from selling business. It spent HK$17,245 Mil on purchasing investments. It gained HK$13,525 Mil from selling investments. It paid HK$424Mil for net Intangibles purchase and sale. And it received HK$3,352 Mil from other investing activities. In all, China Resources Pharmaceutical Group spent HK$2,570 Mil on investment activities in financial market and operating subsidiaries for the six months ended in Dec. 2023.


China Resources Pharmaceutical Group Cash Flow from Investing Historical Data

The historical data trend for China Resources Pharmaceutical Group's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group Cash Flow from Investing Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,008.42 -2,252.43 -9,198.84 -914.86 -2,261.16

China Resources Pharmaceutical Group Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,738.27 -1,629.75 637.76 309.04 -2,570.20

China Resources Pharmaceutical Group Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

China Resources Pharmaceutical Group's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

China Resources Pharmaceutical Group's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-2,261 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Resources Pharmaceutical Group  (HKSE:03320) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

China Resources Pharmaceutical Group's purchase of property, plant, equipment for the six months ended in Dec. 2023 was HK$-1,566 Mil. It means China Resources Pharmaceutical Group spent HK$1,566 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

China Resources Pharmaceutical Group's sale of property, plant, equipment for the six months ended in Dec. 2023 was HK$167 Mil. It means China Resources Pharmaceutical Group gained HK$167 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

China Resources Pharmaceutical Group's purchase of business for the six months ended in Dec. 2023 was HK$-76 Mil. It means China Resources Pharmaceutical Group spent HK$76 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

China Resources Pharmaceutical Group's sale of business for the six months ended in Dec. 2023 was HK$-304 Mil. It means China Resources Pharmaceutical Group gained HK$-304 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

China Resources Pharmaceutical Group's purchase of investment for the six months ended in Dec. 2023 was HK$-17,245 Mil. It means China Resources Pharmaceutical Group spent {stock_data.stock.currency_symbol}}17,245 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

China Resources Pharmaceutical Group's sale of investment for the six months ended in Dec. 2023 was HK$13,525 Mil. It means China Resources Pharmaceutical Group gained HK$13,525 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

China Resources Pharmaceutical Group's net Intangibles purchase and sale for the six months ended in Dec. 2023 was HK$-424 Mil. It means China Resources Pharmaceutical Group paid HK$424 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

China Resources Pharmaceutical Group's cash from discontinued investing activities for the six months ended in Dec. 2023 was 0 Mil. It means China Resources Pharmaceutical Group paid HK$0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

China Resources Pharmaceutical Group's cash from other investing activities for the six months ended in Dec. 2023 was HK$3,352 Mil. It means China Resources Pharmaceutical Group received HK$3,352 Mil from other investing activities.


China Resources Pharmaceutical Group Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Pharmaceutical Group (HKSE:03320) Business Description

Traded in Other Exchanges
Address
26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG
CR Pharma, is a vertically integrated conglomerate that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the third largest drug distributor by revenue, with a strong presence in Eastern, Northern, and Southern China. Its drug manufacturing segment primarily consists of four listed subsidiaries, Dong E E Jiao, CR Sanjiu, CR Double Crane, and Jiangzhong Pharmaceutical, which are well-known makers of over-the-counter traditional Chinese medicines (or TCM), health supplements, and prescription drugs. We estimate the company's operating income is approximately 53% distribution, 46% manufacturing, and less than 1% retail pharmacies.
Executives
Bei Jing Guo You Zi Ben Yun Ying Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you

China Resources Pharmaceutical Group (HKSE:03320) Headlines

No Headlines